Remibrutinib
id:
remibrutinib-199-10199978
title:
Remibrutinib
text:
Remibrutinib is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria. In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Remibrutinib
date created:
date modified:
2024-04-24T21:49:38Z
main entity:
{"identifier":"Q123499462","url":"https://www.wikidata.org/entity/Q123499462"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/4/41/Remibrutinib.svg","width":900,"height":615}
fields total:
13
integrity:
15